A compound preparation for treating painful diabetic neuropathy and its application

Abstract

The invention belongs to the field of medicine and provides a compound preparation used for treating diabetic painful sensory neuropathy and applications thereof. The compound preparation comprises following medicinal components by weight: 45-55 parts of cilostazol, 0.9-1.1 parts of mecobalamin and 180-220 parts of anemarrhena-lily extract powder. The invention also provides a preparing method and pharmaceutical purposes of the compound preparation. The compound preparation can be used for treating the diabetic painful sensory neuropathy, and has characteristics of good treating effects, less side effects and no addiction.

Description

technical field

[0001] The invention belongs to the field of medicine, in particular to a compound preparation for treating painful diabetic neuropathy and its application. Background technique

[0002] There are 240 million diabetic patients in the world, and diabetes has become the third major disease that seriously endangers human health. Diabetic peripheral neuropathy (DPN) is one of the most common chronic complications of diabetes, with a prevalence of about 60%. DPN has an insidious onset, a slow process, and a wide range of involvement, which may involve somatic and autonomic nerves. Common symptoms include numbness, hyperesthesia, burning pain, electric shock or needle-like pain, deep muscle pain, and dyskinesia, etc., which are more common in the lower limbs, aggravated at night, and even lead to foot ulcers, gangrene, and even amputation, seriously affecting the patient's health. Quality of Life.

[0003] Subjective symptoms such as limb numbness, needle-like s...

Examples

Embodiment 1

[0054] Embodiment 1 compound preparation capsule preparation

[0055] Table 1-1

[0056]

[0057] Preparation process: prepare 1000 grains of product according to the above formula, the specific preparation method is as follows:

[0058] According to the usual capsule operation, take Anemarrhena lily extract powder, cilostazol, and methylcobalamin according to the formula in Table 1-1, dry granulate, pack into suitable capsules, and seal to obtain 1000 capsules.

Embodiment 2

[0059] Embodiment 2 Improves the research of peripheral neuropathy in diabetic rats

[0060] 1. Research purpose: To observe the improving effect of the compound preparation capsule of the present invention on peripheral neuropathy in diabetic rats.

[0061] 2. Test drug: Prepared by Formula 1 of Example 1.

[0062] 3. Animal source, species, strain: Sprague-Dawley (SD) rats, body weight: 200-240g; sex: male; total number of animals: 55; purchased from Shanghai Experimental Animal Center, Chinese Academy of Sciences.

[0063] 4. Animal modeling and grouping: All SD rats were adaptively fed for 3 days, 8 SD rats were randomly selected as the normal control group (NC), and the remaining 47 SD rats were used for modeling. After fasting for 12 hours, STZ (streptozotocin) was dissolved in 0.1mol / L citric acid-sodium citrate buffer (pH4.2) to prepare a solution with a concentration of 1%, and a single dose of 60mg / kg By intraperitoneal injection, the normal control group (NC) was ...

Embodiment 3

[0098] Example 3 Study on Alleviating Effects on Diabetic Mice's Anxiety and Depression

[0099] 1. Research purpose: observe the alleviating effect of the compound preparation capsule of the present invention on the anxiety and depression of diabetic mice.

[0100] 2. Test drug: prepared by formula 1 in Example 1

[0101] 3. Animals: source, species, strain: clean grade male ICR mice, body weight: 18-20 g; sex: male; total number of animals: 120; purchased from Shanghai SIPPR-BK Experimental Animal Co., Ltd.

[0102] 4. Animal grouping and administration:

[0103] All mice were adaptively fed for 3 days, 12 mice were randomly selected as the normal control group (NC), and the rest were used for modeling. After fasting for 12 hours, STZ (streptozotocin) was dissolved in 0.1mol / L citric acid-sodium citrate buffer (pH4.2) to prepare a solution with a concentration of 1%, and a single dose of 60mg / kg By intraperitoneal injection, the normal control group (NC) was injected intr...

technical field

[0001] The invention belongs to the field of medicine, in particular to a compound preparation for treating painful diabetic neuropathy and its application. Background technique

[0002] There are 240 million diabetic patients in the world, and diabetes has become the third major disease that seriously endangers human health. Diabetic peripheral neuropathy (DPN) is one of the most common chronic complications of diabetes, with a prevalence of about 60%. DPN has an insidious onset, a slow process, and a wide range of involvement, which may involve somatic and autonomic nerves. Common symptoms include numbness, hyperesthesia, burning pain, electric shock or needle-like pain, deep muscle pain, and dyskinesia, etc., which are more common in the lower limbs, aggravated at night, and even lead to foot ulcers, gangrene, and even amputation, seriously affecting the patient's health. Quality of Life.

[0003] Subjective symptoms such as limb numbness, needle-like s...

Examples

Embodiment 1

[0054] Embodiment 1 compound preparation capsule preparation

[0055] Table 1-1

[0056]

[0057] Preparation process: prepare 1000 grains of product according to the above formula, the specific preparation method is as follows:

[0058] According to the usual capsule operation, take Anemarrhena lily extract powder, cilostazol, and methylcobalamin according to the formula in Table 1-1, dry granulate, pack into suitable capsules, and seal to obtain 1000 capsules.

Embodiment 2

[0059] Embodiment 2 Improves the research of peripheral neuropathy in diabetic rats

[0060] 1. Research purpose: To observe the improving effect of the compound preparation capsule of the present invention on peripheral neuropathy in diabetic rats.

[0061] 2. Test drug: Prepared by Formula 1 of Example 1.

[0062] 3. Animal source, species, strain: Sprague-Dawley (SD) rats, body weight: 200-240g; sex: male; total number of animals: 55; purchased from Shanghai Experimental Animal Center, Chinese Academy of Sciences.

[0063] 4. Animal modeling and grouping: All SD rats were adaptively fed for 3 days, 8 SD rats were randomly selected as the normal control group (NC), and the remaining 47 SD rats were used for modeling. After fasting for 12 hours, STZ (streptozotocin) was dissolved in 0.1mol / L citric acid-sodium citrate buffer (pH4.2) to prepare a solution with a concentration of 1%, and a single dose of 60mg / kg By intraperitoneal injection, the normal control group (NC) was ...

Embodiment 3

[0098] Example 3 Study on Alleviating Effects on Diabetic Mice's Anxiety and Depression

[0099] 1. Research purpose: observe the alleviating effect of the compound preparation capsule of the present invention on the anxiety and depression of diabetic mice.

[0100] 2. Test drug: prepared by formula 1 in Example 1

[0101] 3. Animals: source, species, strain: clean grade male ICR mice, body weight: 18-20 g; sex: male; total number of animals: 120; purchased from Shanghai SIPPR-BK Experimental Animal Co., Ltd.

[0102] 4. Animal grouping and administration:

[0103] All mice were adaptively fed for 3 days, 12 mice were randomly selected as the normal control group (NC), and the rest were used for modeling. After fasting for 12 hours, STZ (streptozotocin) was dissolved in 0.1mol / L citric acid-sodium citrate buffer (pH4.2) to prepare a solution with a concentration of 1%, and a single dose of 60mg / kg By intraperitoneal injection, the normal control group (NC) was injected intr...

Images